A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
This is a multicenter, double-blind study in 1438 participants, who will be randomized to receive subcutaneous (SC) injections of either eplontersen or placebo once every 4 weeks. Participants will also receive daily supplemental doses of the recommended daily allowance of vitamin A.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037, United States
San Francisco, California 94143, United States
Washington D.C., District of Columbia 20037, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires C1428ART, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
Uwajima-shi, Ehime 798-8510, Japan
Kitakyushu-shi, Fukuoka 807-8555, Japan
Kurume-shi, Fukuoka 830-0011, Japan
Shinjuku-Ku, Tokyo 160-8582, Japan
Warsaw, 04-628, Poland
Lisbon, 1169-024, Portugal